abstract |
An agent that reduces the expression of the LDHA gene for use in treating a subject who has PH1, PH2, PH3 (primary hyperoxaluria type 1, type 2 or type 3) or idiopathic hyperoxaluria, wherein the agent is an iRNA molecule or a single-stranded antisense oligonucleotide that targets lactate dehydrogenase RNA. |